Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Testing Times For India’s Drug Patent Law

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - A couple of ongoing landmark developments, both involving the same drug, are putting India's patent law under a severe test and are expected to decide how multinational pharmaceutical firms will view the Indian market
Advertisement

Related Content

PharmAsia News India Pharma Roundup: Natco, Strides Arcolab, Glenmark, Ranbaxy/Pfizer, Merck
PharmAsia News India Pharma Roundup: Natco, Strides Arcolab, Glenmark, Ranbaxy/Pfizer, Merck
Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
Hearing On Natco Plea To Make Generic Version Of Roche, Pfizer Cancer Drugs Extended To March
Hearing On Natco Plea To Make Generic Version Of Roche, Pfizer Cancer Drugs Extended To March
IP Protection Concerns Grow In India, PhRMA Says
Insider Analysis: The Glivec Patent Saga – Effectuating “Efficacious” Patent Norms In India
Insider Analysis: The Glivec Patent Saga – Effectuating “Efficacious” Patent Norms In India
Advertisement
UsernamePublicRestriction

Register

SC067816

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel